glp 1 drugs and fatty liver Multiple target tissue effects of GLP-1 analogues on non-alcoholic disease (NAFLD) non-alcoholic steatohepatitis (NASH) GLP-1s Are Just Getting Started:
Description
Future studies should focus on conducting trials to provide more robust evidence on the comparative effectiveness of liraglutide and semaglutide in managing WR post-bariatric surgery
[DOI] [PubMed] [Google Scholar] 165.Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
A study published last summer by JAMA Oncology looked at GLP-1 use and 14 obesity-related cancers and found that while the weight-loss drug lowered the risk of most cancers, there was a nonsignificant increased risk of kidney cancer particularly among people younger than 65
2013;304(2):F137F144
doi: 10.3390/ijms20081940 77 BaiFZhangLHZhangWWZhengRHEskewJRBennettJet al
